Teva Pharmaceutical Industries Limited (TEVA): What’s Inside the Story?

On Friday, shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) marked $15.36 per share versus a previous $15.14 closing price. With having a 1.45% gain, an insight into the fundamental values of Teva Pharmaceutical Industries Limited, investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. TEVA showed a fall of -0.39% within its YTD performance, with highs and lows between $14.04 – $25.96 during the period of 52 weeks, compared to the simple moving average of -22.72% in the period of the last 200 days. SunTrust equity researchers changed the status of Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares to a “Hold” rating in the report published on March 20th, 2019. Other analysts, including UBS, also published their reports on TEVA shares. UBS repeated the rating from the previous report, marking TEVA under “Buy” rating, in the report published on March 7th, 2019. Additionally, TEVA shares got another “Equal-Weight” rating from Morgan Stanley, setting a target price of $17 on the company’s shares, according to the report published in March 6th, 2019. On February 20th, 2019, Mizuho Downgrade an Neutral rating and increased its price target from $25 to $18. On the other hand, Raymond James Upgrade the “Outperform” rating for TEVA shares, as published in the report on February 14th, 2019. UBS seems to be going bullish on the price of TEVA shares, based on the price prediction for TEVA. Another “Neutral” rating came from Piper Jaffray.

Spotlight

Spotlight

Related News